# What Mouse Heart Scarring Studies Can Tell Us About Serelaxin

- Article ID: research-187
- Product: Human Relaxin-2 (human-relaxin-2-588, human-relaxin-2-562)
- Canonical page: https://heritagebiolabs.com/research-library/articles/187-what-mouse-heart-scarring-studies-can-tell-us-about-serelaxin
- Product collection: https://heritagebiolabs.com/research-library/products/human-relaxin-2
- Product page: https://heritagebiolabs.com/product/human-relaxin-2-588
- Product page: https://heritagebiolabs.com/product/human-relaxin-2-562
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2019, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short amino-acid chain connected by peptide bonds. Some hormones made of peptides can affect signaling in the cells that maintain tissue structure. Human relaxin-2 is one such hormone. Researchers study its recombinant form, serelaxin, in models of fibrosis, a process in which excessive scar-like material accumulates. In the heart, fibrosis can change how tissue moves. A 2026 paper asked how serelaxin affected scarring measurements in mouse heart injury models and whether those changes were seen in the presence of another medicine. [1]

Ziqiao Wang and colleagues examined two models, including one involving injury resembling a heart attack. They compared serelaxin with perindopril, an ACE inhibitor, and included comparisons involving the two materials together. They evaluated scarring in the left ventricle and several measures of its function. Under the tested conditions, the authors found lower measures of fibrosis with serelaxin and reported that the pattern persisted when perindopril was present. The paper also measured blood pressure, helping separate a tissue observation from a change in pressure in those mice. [1]

The experiment was designed to study interactions under defined conditions. A positive result in the model does not determine how a person taking perindopril would respond to serelaxin, or whether the balance of benefits and risks would be favorable. Mouse models capture parts of a disease process. They do not recreate the many causes of heart failure, the histories of individual patients or the effects of all medicines those patients may already receive. [1, 2]

The large earlier RELAX-AHF-2 trial did not establish a benefit for serelaxin on its primary outcomes in acute heart failure. That clinical result and the newer mouse result answer different questions. The mouse paper supports further investigation of fibrosis and signaling. The clinical result sets a limit on claims about outcomes in hospitalized patients. [1, 2]

## Sources

1. Wang Z et al. Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease. Life Sciences (online 2026-05-22). <https://pubmed.ncbi.nlm.nih.gov/42176886/>
2. Metra M et al. Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine (2019-08-22). <https://pubmed.ncbi.nlm.nih.gov/31433919/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 038 - Human Relaxin-2 and IGF-1 Human.docx; article 187; content SHA-256 870d986da38dccda2433b418f0cbc2a2894f81aa448776262005f25a6f9f44cd.
